Maridea Wealth Management LLC Purchases New Shares in Cellebrite DI Ltd. $CLBT

Maridea Wealth Management LLC purchased a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 93,987 shares of the company’s stock, valued at approximately $1,295,000.

A number of other hedge funds have also recently added to or reduced their stakes in CLBT. Towarzystwo Funduszy Inwestycyjnych PZU SA increased its position in Cellebrite DI by 81.0% in the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after acquiring an additional 850 shares in the last quarter. CWM LLC lifted its position in shares of Cellebrite DI by 57.0% during the fourth quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $44,000 after purchasing an additional 889 shares in the last quarter. SkyView Investment Advisors LLC grew its stake in shares of Cellebrite DI by 2.6% during the second quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company’s stock valued at $597,000 after purchasing an additional 970 shares during the last quarter. Alamea Verwaltungs GmbH increased its holdings in shares of Cellebrite DI by 4.3% in the fourth quarter. Alamea Verwaltungs GmbH now owns 24,648 shares of the company’s stock valued at $444,000 after purchasing an additional 1,018 shares in the last quarter. Finally, Pacer Advisors Inc. increased its holdings in shares of Cellebrite DI by 45.1% in the fourth quarter. Pacer Advisors Inc. now owns 3,981 shares of the company’s stock valued at $72,000 after purchasing an additional 1,238 shares in the last quarter. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Price Performance

CLBT opened at $13.76 on Friday. The company has a market cap of $3.43 billion, a price-to-earnings ratio of 49.14, a price-to-earnings-growth ratio of 1.56 and a beta of 1.17. The firm has a 50 day simple moving average of $13.21 and a 200 day simple moving average of $14.73. Cellebrite DI Ltd. has a fifty-two week low of $11.02 and a fifty-two week high of $19.98.

Insider Buying and Selling at Cellebrite DI

In other news, CRO Marcus Jewell sold 12,658 shares of the firm’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $12.77, for a total value of $161,642.66. Following the transaction, the executive directly owned 440,101 shares in the company, valued at $5,620,089.77. This trade represents a 2.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last 90 days, insiders sold 13,269 shares of company stock valued at $169,592. Corporate insiders own 5.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on CLBT. Wall Street Zen upgraded shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. DA Davidson assumed coverage on Cellebrite DI in a research note on Wednesday, May 27th. They issued a “buy” rating and a $20.00 target price for the company. Needham & Company LLC lowered their target price on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Finally, Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $21.40.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.